SK2812000A3 - Synthetic divalent slex containing polylactosamines and methods for use - Google Patents

Synthetic divalent slex containing polylactosamines and methods for use Download PDF

Info

Publication number: SK2812000A3
Authority: SK; Slovakia
Prior art keywords: patient; glycan; fuc; selectin; polylactosamine
Prior art date: 1997-09-05

Application number

SK281-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Ossi Renkonen

Risto Renkonen

Original Assignee

Glycim Oy

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-05

Filing date

1998-09-04

Publication date

2001-03-12

1998-09-04 Application filed by Glycim Oy filed Critical Glycim Oy

2001-03-12 Publication of SK2812000A3 publication Critical patent/SK2812000A3/sk

Links

238000000034 method Methods 0.000 title claims description 54
229920001542 oligosaccharide Polymers 0.000 claims abstract description 81
150000002482 oligosaccharides Chemical class 0.000 claims abstract description 80
239000000203 mixture Substances 0.000 claims abstract description 67
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
208000035143 Bacterial infection Diseases 0.000 claims abstract description 5
208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 5
LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical group O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 claims description 45
101710188695 Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims description 34
102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims description 34
102100021333 Alpha-(1,3)-fucosyltransferase 7 Human genes 0.000 claims description 27
101710188694 Alpha-(1,3)-fucosyltransferase 7 Proteins 0.000 claims description 25
210000001519 tissue Anatomy 0.000 claims description 23
230000015572 biosynthetic process Effects 0.000 claims description 19
206010028980 Neoplasm Diseases 0.000 claims description 15
208000015181 infectious disease Diseases 0.000 claims description 15
210000000056 organ Anatomy 0.000 claims description 15
238000003786 synthesis reaction Methods 0.000 claims description 15
210000000265 leukocyte Anatomy 0.000 claims description 14
150000001720 carbohydrates Chemical class 0.000 claims description 13
230000004968 inflammatory condition Effects 0.000 claims description 13
230000000903 blocking effect Effects 0.000 claims description 11
206010027476 Metastases Diseases 0.000 claims description 9
108010001671 galactoside 3-fucosyltransferase Proteins 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 9
201000011510 cancer Diseases 0.000 claims description 8
229930182830 galactose Natural products 0.000 claims description 8
206010003246 arthritis Diseases 0.000 claims description 7
241001465754 Metazoa Species 0.000 claims description 6
210000002216 heart Anatomy 0.000 claims description 6
230000001681 protective effect Effects 0.000 claims description 6
230000008569 process Effects 0.000 claims description 5
208000017520 skin disease Diseases 0.000 claims description 5
206010048768 Dermatosis Diseases 0.000 claims description 4
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
230000002159 abnormal effect Effects 0.000 claims description 4
230000001363 autoimmune Effects 0.000 claims description 4
230000001684 chronic effect Effects 0.000 claims description 4
208000035475 disorder Diseases 0.000 claims description 4
210000004072 lung Anatomy 0.000 claims description 4
208000026310 Breast neoplasm Diseases 0.000 claims description 3
206010060862 Prostate cancer Diseases 0.000 claims description 3
210000003734 kidney Anatomy 0.000 claims description 3
238000013508 migration Methods 0.000 claims description 3
230000005012 migration Effects 0.000 claims description 3
210000002307 prostate Anatomy 0.000 claims description 3
206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
PZUPAGRIHCRVKN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]-5-[3,4,5-trihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound OCC1OC(O)C(O)C(O)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(COC4C(C(O)C(O)CO4)O)O3)O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(COC2C(C(O)C(O)CO2)O)O1 PZUPAGRIHCRVKN-UHFFFAOYSA-N 0.000 claims description 2
208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
210000001185 bone marrow Anatomy 0.000 claims description 2
210000000481 breast Anatomy 0.000 claims description 2
206010017758 gastric cancer Diseases 0.000 claims description 2
210000000496 pancreas Anatomy 0.000 claims description 2
210000000813 small intestine Anatomy 0.000 claims description 2
210000002784 stomach Anatomy 0.000 claims description 2
230000035876 healing Effects 0.000 claims 2
230000002194 synthesizing effect Effects 0.000 claims 2
241000194017 Streptococcus Species 0.000 claims 1
239000004927 clay Substances 0.000 claims 1
210000004087 cornea Anatomy 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
208000010749 gastric carcinoma Diseases 0.000 claims 1
208000028774 intestinal disease Diseases 0.000 claims 1
201000001514 prostate carcinoma Diseases 0.000 claims 1
201000000498 stomach carcinoma Diseases 0.000 claims 1
210000004698 lymphocyte Anatomy 0.000 abstract description 58
238000011282 treatment Methods 0.000 abstract description 48
102000003800 Selectins Human genes 0.000 abstract description 41
108090000184 Selectins Proteins 0.000 abstract description 41
AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 abstract description 36
230000027455 binding Effects 0.000 abstract description 33
201000010099 disease Diseases 0.000 abstract description 15
230000003511 endothelial effect Effects 0.000 abstract description 10
230000028709 inflammatory response Effects 0.000 abstract description 6
208000037819 metastatic cancer Diseases 0.000 abstract 1
208000011575 metastatic malignant neoplasm Diseases 0.000 abstract 1
150000004676 glycans Chemical class 0.000 description 106
108010092694 L-Selectin Proteins 0.000 description 37
102000016551 L-selectin Human genes 0.000 description 37
239000000047 product Substances 0.000 description 25
239000000370 acceptor Substances 0.000 description 24
230000001404 mediated effect Effects 0.000 description 23
210000004027 cell Anatomy 0.000 description 22
SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 20
210000003038 endothelium Anatomy 0.000 description 19
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 17
235000000346 sugar Nutrition 0.000 description 17
210000001165 lymph node Anatomy 0.000 description 16
238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 16
150000001875 compounds Chemical class 0.000 description 15
239000011734 sodium Substances 0.000 description 15
PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 14
206010061218 Inflammation Diseases 0.000 description 14
230000000694 effects Effects 0.000 description 14
230000004054 inflammatory process Effects 0.000 description 14
OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 12
230000002757 inflammatory effect Effects 0.000 description 12
238000001228 spectrum Methods 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 11
230000000451 tissue damage Effects 0.000 description 11
231100000827 tissue damage Toxicity 0.000 description 11
241000700159 Rattus Species 0.000 description 10
230000033581 fucosylation Effects 0.000 description 10
239000000546 pharmaceutical excipient Substances 0.000 description 10
239000000243 solution Substances 0.000 description 10
239000002904 solvent Substances 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
235000014633 carbohydrates Nutrition 0.000 description 9
230000001419 dependent effect Effects 0.000 description 9
210000002889 endothelial cell Anatomy 0.000 description 9
230000007935 neutral effect Effects 0.000 description 9
210000004881 tumor cell Anatomy 0.000 description 9
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 8
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 8
KFEUJDWYNGMDBV-LODBTCKLSA-N N-acetyllactosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KFEUJDWYNGMDBV-LODBTCKLSA-N 0.000 description 8
239000003153 chemical reaction reagent Substances 0.000 description 8
238000000338 in vitro Methods 0.000 description 8
230000009401 metastasis Effects 0.000 description 8
230000006378 damage Effects 0.000 description 7
230000002093 peripheral effect Effects 0.000 description 7
230000032258 transport Effects 0.000 description 7
235000010523 Cicer arietinum Nutrition 0.000 description 6
244000045195 Cicer arietinum Species 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
LQEBEXMHBLQMDB-UHFFFAOYSA-N GDP-L-fucose Natural products OC1C(O)C(O)C(C)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C3=C(C(N=C(N)N3)=O)N=C2)O1 LQEBEXMHBLQMDB-UHFFFAOYSA-N 0.000 description 6
LQEBEXMHBLQMDB-JGQUBWHWSA-N GDP-beta-L-fucose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=C(C(NC(N)=N3)=O)N=C2)O1 LQEBEXMHBLQMDB-JGQUBWHWSA-N 0.000 description 6
108010006232 Neuraminidase Proteins 0.000 description 6
-1 TQ-1 Proteins 0.000 description 6
108010005774 beta-Galactosidase Proteins 0.000 description 6
230000021164 cell adhesion Effects 0.000 description 6
230000000295 complement effect Effects 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
238000004816 paper chromatography Methods 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
239000000126 substance Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
108010024212 E-Selectin Proteins 0.000 description 5
102100023471 E-selectin Human genes 0.000 description 5
102000005348 Neuraminidase Human genes 0.000 description 5
102100023472 P-selectin Human genes 0.000 description 5
239000012505 Superdex™ Substances 0.000 description 5
230000001154 acute effect Effects 0.000 description 5
230000002255 enzymatic effect Effects 0.000 description 5
230000036541 health Effects 0.000 description 5
235000020256 human milk Nutrition 0.000 description 5
210000004251 human milk Anatomy 0.000 description 5
239000003446 ligand Substances 0.000 description 5
238000004949 mass spectrometry Methods 0.000 description 5
125000005630 sialyl group Chemical group 0.000 description 5
231100000331 toxic Toxicity 0.000 description 5
230000002588 toxic effect Effects 0.000 description 5
210000003462 vein Anatomy 0.000 description 5
208000035473 Communicable disease Diseases 0.000 description 4
108010035766 P-Selectin Proteins 0.000 description 4
208000038016 acute inflammation Diseases 0.000 description 4
230000006022 acute inflammation Effects 0.000 description 4
NIGUVXFURDGQKZ-UQTBNESHSA-N alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O NIGUVXFURDGQKZ-UQTBNESHSA-N 0.000 description 4
238000005571 anion exchange chromatography Methods 0.000 description 4
238000003556 assay Methods 0.000 description 4
102000005936 beta-Galactosidase Human genes 0.000 description 4
239000002775 capsule Substances 0.000 description 4
208000037976 chronic inflammation Diseases 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
238000002523 gelfiltration Methods 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
239000000843 powder Substances 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
125000005629 sialic acid group Chemical group 0.000 description 4
150000008163 sugars Chemical class 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
KFEUJDWYNGMDBV-UHFFFAOYSA-N (N-Acetyl)-glucosamin-4-beta-galaktosid Natural products OC1C(NC(=O)C)C(O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 KFEUJDWYNGMDBV-UHFFFAOYSA-N 0.000 description 3
XLEYFDVVXLMULC-UHFFFAOYSA-N 2',4',6'-trihydroxyacetophenone Chemical compound CC(=O)C1=C(O)C=C(O)C=C1O XLEYFDVVXLMULC-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
TXCIAUNLDRJGJZ-BILDWYJOSA-N CMP-N-acetyl-beta-neuraminic acid Chemical class O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@]1(C(O)=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=C(N)C=C2)=O)O1 TXCIAUNLDRJGJZ-BILDWYJOSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
108010019236 Fucosyltransferases Proteins 0.000 description 3
102000006471 Fucosyltransferases Human genes 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 3
102000004856 Lectins Human genes 0.000 description 3
108090001090 Lectins Proteins 0.000 description 3
HESSGHHCXGBPAJ-UHFFFAOYSA-N N-acetyllactosamine Natural products CC(=O)NC(C=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O HESSGHHCXGBPAJ-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
108090000141 Sialyltransferases Proteins 0.000 description 3
102000003838 Sialyltransferases Human genes 0.000 description 3
108010046516 Wheat Germ Agglutinins Proteins 0.000 description 3
230000009471 action Effects 0.000 description 3
239000000853 adhesive Substances 0.000 description 3
230000001070 adhesive effect Effects 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 3
102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
230000002458 infectious effect Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
239000002523 lectin Substances 0.000 description 3
239000002502 liposome Substances 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
244000005700 microbiome Species 0.000 description 3
238000000159 protein binding assay Methods 0.000 description 3
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000007909 solid dosage form Substances 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000002054 transplantation Methods 0.000 description 3
WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
PNIWLNAGKUGXDO-LNCRCTFVSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r)-5-amino-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical class O[C@@H]1[C@@H](N)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 PNIWLNAGKUGXDO-LNCRCTFVSA-N 0.000 description 2
238000005160 1H NMR spectroscopy Methods 0.000 description 2
108010083651 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase Proteins 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
101100377506 Drosophila melanogaster 14-3-3zeta gene Proteins 0.000 description 2
206010015866 Extravasation Diseases 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
102000005744 Glycoside Hydrolases Human genes 0.000 description 2
108010031186 Glycoside Hydrolases Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000819497 Homo sapiens Alpha-(1,3)-fucosyltransferase 7 Proteins 0.000 description 2
101001018097 Homo sapiens L-selectin Proteins 0.000 description 2
102100033467 L-selectin Human genes 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
206010024453 Ligament sprain Diseases 0.000 description 2
OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
102100028688 Putative glycosylation-dependent cell adhesion molecule 1 Human genes 0.000 description 2
206010063837 Reperfusion injury Diseases 0.000 description 2
208000010040 Sprains and Strains Diseases 0.000 description 2
HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000002924 anti-infective effect Effects 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000006020 chronic inflammation Effects 0.000 description 2
208000037893 chronic inflammatory disorder Diseases 0.000 description 2
230000004087 circulation Effects 0.000 description 2
239000000356 contaminant Substances 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
230000000212 effect on lymphocytes Effects 0.000 description 2
239000003480 eluent Substances 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
238000006911 enzymatic reaction Methods 0.000 description 2
230000036251 extravasation Effects 0.000 description 2
239000012467 final product Substances 0.000 description 2
125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 2
210000003714 granulocyte Anatomy 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000008297 liquid dosage form Substances 0.000 description 2
238000005567 liquid scintillation counting Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
150000002772 monosaccharides Chemical group 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
210000002826 placenta Anatomy 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
230000002265 prevention Effects 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
125000006853 reporter group Chemical group 0.000 description 2
230000004044 response Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
108010012704 sulfated glycoprotein p50 Proteins 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
KUUVQVSHGLHAKZ-UHFFFAOYSA-N thionine Chemical compound C=1C=CC=CSC=CC=1 KUUVQVSHGLHAKZ-UHFFFAOYSA-N 0.000 description 2
238000012546 transfer Methods 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
HORYNJCIACQHGZ-BHVWUGLYSA-N 1-[(3R,4R,5S,6R)-3-amino-2,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]ethanone Chemical group C(C)(=O)C1(O)[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO HORYNJCIACQHGZ-BHVWUGLYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
101800000733 Angiotensin-2 Proteins 0.000 description 1
102400000345 Angiotensin-2 Human genes 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000421809 Brisaster fragilis Species 0.000 description 1
102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 1
102000015689 E-Selectin Human genes 0.000 description 1
101150096822 Fuca1 gene Proteins 0.000 description 1
102100040510 Galectin-3-binding protein Human genes 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
101000622123 Homo sapiens E-selectin Proteins 0.000 description 1
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
208000005016 Intestinal Neoplasms Diseases 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
229940121930 L-selectin antagonist Drugs 0.000 description 1
108010076118 L-selectin counter-receptors Proteins 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
239000007993 MOPS buffer Substances 0.000 description 1
108010063954 Mucins Proteins 0.000 description 1
101710139349 Mucosal addressin cell adhesion molecule 1 Proteins 0.000 description 1
102100028793 Mucosal addressin cell adhesion molecule 1 Human genes 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000029549 Muscle injury Diseases 0.000 description 1
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
238000012565 NMR experiment Methods 0.000 description 1
101710137390 P-selectin glycoprotein ligand 1 Proteins 0.000 description 1
102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 description 1
241001524178 Paenarthrobacter ureafaciens Species 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
102100028755 Sialidase-2 Human genes 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
241001288016 Streptococcus gallolyticus Species 0.000 description 1
101800001271 Surface protein Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
206010044541 Traumatic shock Diseases 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
FTNIPWXXIGNQQF-UHFFFAOYSA-N UNPD130147 Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(OC4C(OC(O)C(O)C4O)CO)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O FTNIPWXXIGNQQF-UHFFFAOYSA-N 0.000 description 1
LUEWUZLMQUOBSB-UHFFFAOYSA-N UNPD55895 Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(O)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O LUEWUZLMQUOBSB-UHFFFAOYSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
GVXWGQLSDZJHFY-DIZWBPKDSA-N alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-D-GlcpNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 GVXWGQLSDZJHFY-DIZWBPKDSA-N 0.000 description 1
NIGUVXFURDGQKZ-KRAHZTDDSA-N alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O NIGUVXFURDGQKZ-KRAHZTDDSA-N 0.000 description 1
230000001668 ameliorated effect Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000002001 anti-metastasis Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
LZCZIHQBSCVGRD-UHFFFAOYSA-N benzenecarboximidamide;hydron;chloride Chemical compound [Cl-].NC(=[NH2+])C1=CC=CC=C1 LZCZIHQBSCVGRD-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
OMFRMAHOUUJSGP-IRHGGOMRSA-N bifenthrin Chemical compound C1=CC=C(C=2C=CC=CC=2)C(C)=C1COC(=O)[C@@H]1[C@H](\C=C(/Cl)C(F)(F)F)C1(C)C OMFRMAHOUUJSGP-IRHGGOMRSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
FUHMZYWBSHTEDZ-UHFFFAOYSA-M bispyribac-sodium Chemical compound [Na+].COC1=CC(OC)=NC(OC=2C(=C(OC=3N=C(OC)C=C(OC)N=3)C=CC=2)C([O-])=O)=N1 FUHMZYWBSHTEDZ-UHFFFAOYSA-M 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000003352 cell adhesion assay Methods 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
229960000258 corticotropin Drugs 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
206010014665 endocarditis Diseases 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000007824 enzymatic assay Methods 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000021323 fish oil Nutrition 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
150000002256 galaktoses Chemical class 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
239000003906 humectant Substances 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
201000002313 intestinal cancer Diseases 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000006207 intravenous dosage form Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
101150006217 lex1 gene Proteins 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
239000006166 lysate Substances 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
FJCUPROCOFFUSR-UHFFFAOYSA-N malto-pentaose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 FJCUPROCOFFUSR-UHFFFAOYSA-N 0.000 description 1
UYQJCPNSAVWAFU-UHFFFAOYSA-N malto-tetraose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)O1 UYQJCPNSAVWAFU-UHFFFAOYSA-N 0.000 description 1
FJCUPROCOFFUSR-GMMZZHHDSA-N maltopentaose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O[C@@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@@H](CO)O2)O)[C@@H](CO)O1 FJCUPROCOFFUSR-GMMZZHHDSA-N 0.000 description 1
LUEWUZLMQUOBSB-OUBHKODOSA-N maltotetraose Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O[C@@H]3[C@@H](O[C@@H](O)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-OUBHKODOSA-N 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
210000001589 microsome Anatomy 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
239000002304 perfume Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
239000012264 purified product Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000012552 review Methods 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
230000009450 sialylation Effects 0.000 description 1
IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
238000004329 water eliminated fourier transform Methods 0.000 description 1
210000004269 weibel-palade body Anatomy 0.000 description 1
FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/02—Acyclic radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Oncology (AREA)
Rheumatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Crystallography & Structural Chemistry (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Transplantation (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Saccharide Compounds (AREA)

SK281-2000A 1997-09-05 1998-09-04 Synthetic divalent slex containing polylactosamines and methods for use SK2812000A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US5766097P	1997-09-05	1997-09-05
PCT/FI1998/000688 WO1999012944A2 (fr)	1997-09-05	1998-09-04	POLYLACTOSAMINES SYNTHETIQUES CONTENANT UN sLex DIVALENT ET SES METHODES D'UTILISATION

Publications (1)

Publication Number	Publication Date
SK2812000A3 true SK2812000A3 (en)	2001-03-12

Family

ID=22011973

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK281-2000A SK2812000A3 (en)	1997-09-05	1998-09-04	Synthetic divalent slex containing polylactosamines and methods for use

Country Status (10)

Country	Link
US (1)	US6191271B1 (fr)
EP (1)	EP1015464A2 (fr)
JP (1)	JP2001515912A (fr)
AU (1)	AU9073998A (fr)
CA (1)	CA2302470A1 (fr)
HU (1)	HUP0003418A2 (fr)
NO (1)	NO20001091D0 (fr)
PL (1)	PL339773A1 (fr)
SK (1)	SK2812000A3 (fr)
WO (1)	WO1999012944A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7338932B2 (en)	2000-05-11	2008-03-04	Glycozym Aps	Methods of modulating functions of polypeptide GalNAc-transferases and of screening test substances to find agents herefor, pharmaceutical compositions comprising such agents and the use of such agents for preparing medicaments
EP1282725B1 (fr) *	2000-05-11	2007-05-02	Glycozym ApS	Procedes de modulation de fonctions de galnac-transferases polypeptidiques et de criblage de substances de test pour trouver des agents adaptes
DE60114830T2 (de) *	2000-06-28	2006-08-03	Glycofi, Inc.	Verfahren zur herstellung modifizierter glycoproteine
WO2002089819A1 (fr) *	2001-05-07	2002-11-14	Vereniging Voor Christelijk Wetenschappelijk Onderwijs	Glycoconjugues et utilisations de ceux-ci
US20050203578A1 (en) *	2001-08-15	2005-09-15	Weiner Michael L.	Process and apparatus for treating biological organisms
JP4934802B2 (ja) *	2005-05-30	2012-05-23	国立大学法人信州大学	リンパ系の細胞接着物質、リンパ系薬物輸送材およびそれを含有する薬剤
EP3915999A1 (fr)	2014-03-13	2021-12-01	Universität Basel	Ligands glucidiques qui se lient aux anticorps igm contre la glycoprotéine associée à la myéline
WO2017046172A1 (fr)	2015-09-16	2017-03-23	Universität Basel	Ligands glucidiques se liant à des anticorps dirigés contre des glycoépitopes de glycosphingolipides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5079353A (en)	1987-12-02	1992-01-07	Chembiomed, Ltd.	Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
WO1991019501A1 (fr)	1990-06-15	1991-12-26	Cytel Corporation	Mediateurs d'adherence intercellulaire
US5211937A (en)	1990-07-30	1993-05-18	Glycomed Incorporated	Method of determining a site of inflammation utilizing elam-1 ligands
US5352670A (en)	1991-06-10	1994-10-04	Alberta Research Council	Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides
WO1992022565A1 (fr)	1991-06-10	1992-12-23	Alberta Research Council	Composes modifies de lewisx au sialyl
KR950700314A (ko)	1992-01-31	1995-01-16	아키라 하세가와	루이스형 당쇄 유도체(Lewis-type sugar chain derivative)
JPH0686684A (ja)	1992-05-26	1994-03-29	Monsanto Co	シアロ抱合体の合成
US5426178A (en)	1993-03-31	1995-06-20	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Synthesis of anti-inflammatory compounds, and novel trisaccharides useful in the synthesis of anti-inflammatory compounds
US5409817A (en)	1993-05-04	1995-04-25	Cytel, Inc.	Use of trans-sialidase and sialyltransferase for synthesis of sialylα2→3βgalactosides
US5374541A (en)	1993-05-04	1994-12-20	The Scripps Research Institute	Combined use of β-galactosidase and sialyltransferase coupled with in situ regeneration of CMP-sialic acid for one pot synthesis of oligosaccharides
PL176272B1 (pl)	1993-05-14	1999-05-31	Cytel Corp	Analogi sialilowe Le jako inhibitory adhezji komórkowej
AU7083594A (en)	1993-07-02	1995-01-24	Nippon Shinyaku Co. Ltd.	Galactosylmoranoline derivative
US5559103A (en)	1993-07-21	1996-09-24	Cytel Corporation	Bivalent sialyl X saccharides
AU7467394A (en)	1993-08-23	1995-03-21	Nippon Shinyaku Co. Ltd.	Galactosylmoranoline derivative
HUT77345A (hu)	1994-04-29	1998-03-30	Texas Biotechnology Corporation	E-szelektin, P-szelektin vagy L-szelektin szialil-Lewis x-hez vagy szialil-Lewis a-hoz kapcsolódását gátló mannopiranoziloxi-bifenil származékok és ezeket tartalmazó gyógyszerkészítmények
CZ89098A3 (cs)	1995-09-29	1998-09-16	Glycim Oy	Syntetické polylaktosaminy obsahující až multivalentní sLEX a metody pro jejich použití

1998
- 1998-09-04 HU HU0003418A patent/HUP0003418A2/hu unknown
- 1998-09-04 PL PL98339773A patent/PL339773A1/xx unknown
- 1998-09-04 US US09/148,076 patent/US6191271B1/en not_active Expired - Fee Related
- 1998-09-04 SK SK281-2000A patent/SK2812000A3/sk unknown
- 1998-09-04 WO PCT/FI1998/000688 patent/WO1999012944A2/fr not_active Application Discontinuation
- 1998-09-04 EP EP98942706A patent/EP1015464A2/fr not_active Withdrawn
- 1998-09-04 JP JP2000510750A patent/JP2001515912A/ja active Pending
- 1998-09-04 CA CA002302470A patent/CA2302470A1/fr not_active Abandoned
- 1998-09-04 AU AU90739/98A patent/AU9073998A/en not_active Abandoned
2000
- 2000-03-02 NO NO20001091A patent/NO20001091D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HUP0003418A2 (hu)	2001-02-28
US6191271B1 (en)	2001-02-20
NO20001091L (no)	2000-03-02
JP2001515912A (ja)	2001-09-25
WO1999012944A3 (fr)	1999-08-26
EP1015464A2 (fr)	2000-07-05
WO1999012944A2 (fr)	1999-03-18
PL339773A1 (en)	2001-01-02
CA2302470A1 (fr)	1999-03-18
NO20001091D0 (no)	2000-03-02
AU9073998A (en)	1999-03-29

Publication	Publication Date	Title
Sarkar et al.	1997	Fucosylation of disaccharide precursors of sialyl LewisX inhibit selectin-mediated cell adhesion
US6878819B1 (en)	2005-04-12	Fucosylated oligosaccharides and process for their preparation
Renkonen et al.	1997	Synthesis of a new nanomolar saccharide inhibitor of lymphocyte adhesion: different polylactosamine backbones present multiple sialyl Lewis x determinants to L-selectin in high-affinity mode
Seppo et al.	1996	Synthesis of a tetravalent sialyl Lewis x glycan, a high-affinity inhibitor of L-selectin-mediated lymphocyte binding to endothelium
Oftedal et al.	2014	Can an ancestral condition for milk oligosaccharides be determined? Evidence from the Tasmanian echidna (Tachyglossus aculeatus setosus)
Piller et al.	1986	Identification of a α-NeuAc-(2→ 3)-β-d-galactopyranosyl N-acetyl-β-d-galactosaminyltransferase in human kidney
AU713078B2 (en)	1999-11-25	Synthetic multivalent sLEX containing polylactosamines and methods for use
SK2812000A3 (en)	2001-03-12	Synthetic divalent slex containing polylactosamines and methods for use
Wieruszeski et al.	1985	Structure of two new oligosaccharides isolated from human milk: sialylated lacto-N-fucopentaoses I and II
Warner et al.	1982	Structure analysis of the major oligosaccharides accumulating in canine GM1 gangliosidosis liver.
Adamany et al.	1983	A carbohydrate structural variant of MM glycoprotein (glycophorin A).
CA2110997A1 (fr)	1992-12-23	Methodes utilisees pour la synthese d'oligosaccharides monofucosyles se terminant par des structures di-n-acetyllactosaminyles
Toppila et al.	1999	Enzymatic synthesis of α3′ sialylated and multiply α3fucosylated biantennary polylactosamines: A bivalent [sialyl diLex]‐saccharide inhibited lymphocyte‐endothelium adhesion organ‐selectively
JPH10500939A (ja)	1998-01-27	特定のスルファターゼ酵素類および／または硫酸化阻害剤の投与による炎症の治療
de Vries et al.	1994	Biosynthesis of sialyl-oligomeric-Lewisx and VIM-2 epitopes: site specificity of human milk fucosyltransferase
Kościelak	2001	ABH blood group active glycoconjugates from human red cells.
JPH10508580A (ja)	1998-08-25	Ｅおよびｐセレクチンに対するリガンドのオリゴ糖構造
Natunen et al.	1997	Enzymatic transfer of a β1, 6-linked N-acetylglucosamine to the α-galactose of globo-N-tetraose: in vitro synthesis of a novel hybrid pentasaccharide of lacto-globo type
Toppila et al.	0	Enzymatic synthesis of a30sialylated and multiply a3fucosylated biantennary polylactosamines
CODINGTON et al.	1978	Structural studies on the major glycoprotein of the TA3-HA ascites tumor cell
Pykäria et al.	2000	THE ACCEPTOR AND SITE SPECIFICITY OF 3FUCOSYLTRANSFERASE V.
EP0919563A2 (fr)	1999-06-02	Synthétique comme noyau-2 structures ramifiées comme ligands pour selectine
JP2000279191A (ja)	2000-10-10	オリゴ糖の製造法
Podolsky et al.	1986	D-Galactosyltransferase and its endogenous substrates in chick embryo fibroblasts transformed by Rous sarcoma virus
Veyrieres	1992	The Synthesis of Blood Group I and i Active Oligosaccharides